These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://umairlzbg023563.blogscribble.com/39360448/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide